Chi Mei Medical Center
Chi Mei Medical Center
Tainan, Taiwan6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ATTR-CM: A Multi-country, Non-interventional Disease Registry | Transthyretin Amyloid Cardiopathy | Active, not recruiting | Not stated | 2026-10-06 | NCT06651073 | |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-05-04 | NCT05456256 | |
| Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Active, not recruiting | Phase 2 | 2026-04-28 | NCT03964727 | |
| A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer | Diabetes Complications, Diabetic Foot, Foot Diseases, Foot Ulcer, Leg Ulcer, Nutritional and Metabolic Diseases, Skin Ulcer, Skin and Connective Tissue Diseases, cardiovascular disorder, diabetes mellitus, diabetic neuropathy, diabetic peripheral angiopathy, endocrine system disorder, glucose metabolism disease, injury, metabolic disease, skin disorder, vascular disorder | Recruiting | Phase 3 | 2025-10-02 | NCT05930210 | |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | Phase 3 | 2024-12-31 | NCT04691804 | |
| Taiwan Center of Outcome and Resource Evaluation | Critical Illness, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Not stated | 2024-02-20 | NCT04875260 |